Cargando…
Second primary malignancy after radical prostatectomy in a cohort from the Middle East
BACKGROUND: Data from the Middle East regarding second primary malignancy (SPM) after radical prostatectomy are limited. Our objective was to estimate the overall risk of developing second primary malignancy (SPM) among Middle Eastern men with prostate cancer who underwent surgical extirpation of th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004622/ https://www.ncbi.nlm.nih.gov/pubmed/29922631 http://dx.doi.org/10.1016/j.prnil.2017.09.002 |
_version_ | 1783332551417397248 |
---|---|
author | Shahait, Mohammed Mukherji, Deborah Hamieh, Nadine Nassif, Samer Jabbour, Mark Khauli, Raja Bulbul, Muhammad Abou kheir, Wassim El Hajj, Albert |
author_facet | Shahait, Mohammed Mukherji, Deborah Hamieh, Nadine Nassif, Samer Jabbour, Mark Khauli, Raja Bulbul, Muhammad Abou kheir, Wassim El Hajj, Albert |
author_sort | Shahait, Mohammed |
collection | PubMed |
description | BACKGROUND: Data from the Middle East regarding second primary malignancy (SPM) after radical prostatectomy are limited. Our objective was to estimate the overall risk of developing second primary malignancy (SPM) among Middle Eastern men with prostate cancer who underwent surgical extirpation of their prostate. MATERIALS AND METHODS: We conducted a retrospective study of 406 patients who underwent radical prostatectomy in a tertiary centre and who had no evidence of previous malignancy from 1998 to 2012. Standardized incidence ratios (SIRs) and 95% confidence interval (CI) were calculated to analyze the risk of SPM in our population compared with the general population. Cox-regression models were also conducted to correlate the clinicopathological factors with the development of SPM. RESULTS: After 14 years of follow-up, the incidence rate of SPM was 100.9 per 1,000 person-years. The most frequent SPMs were bladder cancer (n = 11, 27%) followed by hematological malignancies (n = 9, 22%) and lung cancer (n = 7, 17%). The overall risk for men with prostate cancer to develop SPM is lower than the men in the general population (standardized incidence ratios = 0.19; 95% CI: 0.14–0.25). A multivariate analysis failed to correlate any of the clinicopathological factors with the development of SPM. CONCLUSION: Patients with prostate cancer who underwent surgical expiration of their prostate are at lower risk of developing SPM compared with the general population. |
format | Online Article Text |
id | pubmed-6004622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Asian Pacific Prostate Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-60046222018-06-19 Second primary malignancy after radical prostatectomy in a cohort from the Middle East Shahait, Mohammed Mukherji, Deborah Hamieh, Nadine Nassif, Samer Jabbour, Mark Khauli, Raja Bulbul, Muhammad Abou kheir, Wassim El Hajj, Albert Prostate Int Original Article BACKGROUND: Data from the Middle East regarding second primary malignancy (SPM) after radical prostatectomy are limited. Our objective was to estimate the overall risk of developing second primary malignancy (SPM) among Middle Eastern men with prostate cancer who underwent surgical extirpation of their prostate. MATERIALS AND METHODS: We conducted a retrospective study of 406 patients who underwent radical prostatectomy in a tertiary centre and who had no evidence of previous malignancy from 1998 to 2012. Standardized incidence ratios (SIRs) and 95% confidence interval (CI) were calculated to analyze the risk of SPM in our population compared with the general population. Cox-regression models were also conducted to correlate the clinicopathological factors with the development of SPM. RESULTS: After 14 years of follow-up, the incidence rate of SPM was 100.9 per 1,000 person-years. The most frequent SPMs were bladder cancer (n = 11, 27%) followed by hematological malignancies (n = 9, 22%) and lung cancer (n = 7, 17%). The overall risk for men with prostate cancer to develop SPM is lower than the men in the general population (standardized incidence ratios = 0.19; 95% CI: 0.14–0.25). A multivariate analysis failed to correlate any of the clinicopathological factors with the development of SPM. CONCLUSION: Patients with prostate cancer who underwent surgical expiration of their prostate are at lower risk of developing SPM compared with the general population. Asian Pacific Prostate Society 2018-06 2017-09-30 /pmc/articles/PMC6004622/ /pubmed/29922631 http://dx.doi.org/10.1016/j.prnil.2017.09.002 Text en © 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Shahait, Mohammed Mukherji, Deborah Hamieh, Nadine Nassif, Samer Jabbour, Mark Khauli, Raja Bulbul, Muhammad Abou kheir, Wassim El Hajj, Albert Second primary malignancy after radical prostatectomy in a cohort from the Middle East |
title | Second primary malignancy after radical prostatectomy in a cohort from the Middle East |
title_full | Second primary malignancy after radical prostatectomy in a cohort from the Middle East |
title_fullStr | Second primary malignancy after radical prostatectomy in a cohort from the Middle East |
title_full_unstemmed | Second primary malignancy after radical prostatectomy in a cohort from the Middle East |
title_short | Second primary malignancy after radical prostatectomy in a cohort from the Middle East |
title_sort | second primary malignancy after radical prostatectomy in a cohort from the middle east |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004622/ https://www.ncbi.nlm.nih.gov/pubmed/29922631 http://dx.doi.org/10.1016/j.prnil.2017.09.002 |
work_keys_str_mv | AT shahaitmohammed secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT mukherjideborah secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT hamiehnadine secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT nassifsamer secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT jabbourmark secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT khauliraja secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT bulbulmuhammad secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT aboukheirwassim secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast AT elhajjalbert secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast |